Novavax (NVAX)
(Delayed Data from NSDQ)
$11.99 USD
+0.03 (0.25%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.99 USD
+0.03 (0.25%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Zacks News
Novavax's (NVAX) Q1 Loss Widens, Revenues Beat, Shares Down
by Zacks Equity Research
Novavax (NVAX) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Shares fall in after-hours trading.
Devon Energy, Bilibili, Novavax, Roblox and Wynn Resorts highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Devon Energy, Bilibili, Novavax, Roblox and Wynn Resorts highlighted as Zacks Bull and Bear of the Day
Indexes Sink into Close, Q1 Reports for NVAX, WYNN & More
by Mark Vickery
The Nasdaq was -2.55% Monday, its worst single trading day in almost two months.
Novavax (NVAX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -15.09% and 53.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $160.50, marking a -8.81% move from the previous day.
Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the first quarter, driven by revived demand.
Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.
Novavax (NVAX) Stock Moves -0.25%: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $236.93, marking a -0.25% move from the previous day.
Novavax Vaccine to Get U.S. Approval? ETFs to Benefit
by Sanghamitra Saha
Novavax (NVAX) is reportedly set to receive the fourth authorization for COVID-19 vaccine in the United States.
Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FAD
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming first-quarter earnings call, investor focus is expected to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
Novavax (NVAX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $207.61, marking a +0.15% move from the previous day.
Novavax (NVAX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $202.09, marking a +0.37% move from the previous day.
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $179.74 in the latest trading session, marking a +1.97% move from the prior day.
Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
Company News for Apr 7, 2021
by Zacks Equity Research
Companies in The News Are: ILMN, NVAX, MRNA, BP.
Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Novavax (NVAX) Stock Moves -0.25%: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $173.32, marking a -0.25% move from the previous day.
Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.
Follow Dave Portnoy & Reddit Rebellion with These ETFs
by Neena Mishra
These ETFs track social media sentiment & market trends.
Bull of the Day: Meridian Bioscience (VIVO)
by Kevin Cook
Delay in FDA approval for latest COVID test hasn't altered growth or value at 3X sales
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $225.46, marking a +1.45% move from the previous day.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
A Pureplay ETF on Leisure from SonicShares in the Offing
by Sanghamitra Saha
SonicShares recently filed for an Airlines, Hotels, Cruise Lines ETF.
Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More
by Zacks Equity Research
The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.